Tag Archives: SmithKline

Are pharmaceutical mega-mergers in the public interest?

Posted on May 2, 2014 by Barbara Arzymanow

The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading →

Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology | Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover | Leave a comment

	Lali Sekhon, MD on Tackling obesity – What the UK…
	Author Ingrid Hall on Ovarian Cancer – Make wo…
	David Bradley on 2020health comments on GMC rep…
	20 things to make yo… on Equal treatment for Depression…
	David Bradley on Guest Blogspot: Misleading, Bi…

Tag Archives: SmithKline

Are pharmaceutical mega-mergers in the public interest?

TwentyTwentyTweets

Email Subscription

Recent Posts

Pages

Opinions

Categories